INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
Dec 08, 2009 |
Director
Trans History: 742
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 187,500 | -- | -- |
Dec 17, 2008 |
Director, President & CEO
Trans History: 427
|
Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 187,500 | -- | 312,500 |
Oct 30, 2015 |
Director, President Regeneron Laboratori
Trans History: 673
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 182,818 | $11.64 | 682,818 |
Oct 30, 2015 |
Director, President Regeneron Laboratori
Trans History: 673
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 182,818 | -- | -- |
Dec 19, 2005 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 673
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 182,818 | -- | 182,818 |
Jun 14, 2005 |
Director
Trans History: 742
|
Director | Form 4 | Other acquisition or disposition (describe transaction) | 182,171 | -- | 339,396 |
Jun 14, 2005 |
Director
Trans History: 742
|
Director | Form 4 | Other acquisition or disposition (describe transaction) | 182,171 | -- | 63,511 |
Aug 03, 2017 |
Director, President and CSO
Trans History: 673
|
Director, President and CSO | Form 4 | Bona fide gift | 176,223 | -- | 176,223 |
Aug 03, 2017 |
Director, President and CSO
Trans History: 673
|
Director, President and CSO | Form 4 | Bona fide gift | 176,223 | -- | 155,406 |
Jul 21, 2017 |
Director, President and CSO
Trans History: 673
|
Director, President and CSO | Form 4 | Bona fide gift | 176,223 | -- | 323,777 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.